

WHO urges nations to join global shared vaccine bid

August 18 2020, by Robin Millard



Around the world, 29 potential vaccines are currently being tested on humans

The WHO wrote to every country on Tuesday urging them to quickly join its global shared vaccine programme—and spelled out who would get its eventual coronavirus jabs first.

The World Health Organization's director-general Tedros Adhanom Ghebreyesus said that without vaccinating the planet's highest-risk populations simultaneously, it would be impossible to rebuild the global economy.

And he said the most exposed 20 percent of each country's population—including front-line health workers, adults over 65 and those with pre-existing conditions—would be targeted in the first wave of vaccinations, once the WHO-led COVAX shared facility can roll out a proven safe and effective vaccine.

"The fastest way to end this pandemic and to reopen economies is to start by protecting the highest risk populations everywhere, rather than the entire populations of just some countries," Tedros told a virtual press conference.

The novel coronavirus has killed nearly 775,000 people and infected almost 22 million since the outbreak emerged in China last December, according to a tally from official sources compiled by AFP.

Two-phase rollout

Researchers and pharmaceutical giants are racing to produce a vaccine, with nine of the 29 currently being tested on humans forming part of the COVAX Global Vaccines Facility.

"If there's a winner in vaccines, we'll have one, there's absolutely no question," said WHO advisor Bruce Aylward.

Some 92 countries are signed up to COVAX—an effort to pool the costs and rewards of finding, producing and distributing effective vaccines—while a further 80 have expressed interest but are yet to commit fully.

The WHO wants countries to signal a firm interest by August 31.

"The COVAX Global Vaccines Facility is the critical mechanism for joint procurement and pooling risk across multiple vaccines, which is why today I sent a letter to every member state encouraging them to join," Tedros said.



World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus says people most exposed to the coronavirus should be vaccinated first

He specified that the allocation of vaccines would be rolled out in two phases.

In the first, doses would be allocated proportionally to all participating countries simultaneously, in a bid to reduce the overall global risk.

In the second phase, individual countries' threat and vulnerability level will then come into play.

Herd immunity

Tedros said front-line workers in health and social care settings would get first phase priority, "as they are essential to treat and protect the population, and come in close contact with high-mortality risk groups" he explained.

He said initial data showed that adults over 65 and those with particular pre-existing conditions were at the highest risk of dying from COVID-19.

"For most countries, a phase one allocation that builds up to 20 percent of the population would cover most of the at-risk groups," said Tedros.

"If we don't protect these highest risk people from the virus everywhere and at the same time, we can't stabilise health systems and rebuild the global economy."

In the absence of a vaccine, the WHO scotched notions that 50 percent of people having developed resistance to the new coronavirus would be enough to achieve "herd immunity" and thereby stop transmission.

WHO emergencies director Michael Ryan said the planet was "nowhere close to the levels of immunity required to stop this disease".

People should "not live in hope of herd immunity being our salvation. Right now, that is not a solution," he added.

Aylward said it would take "very high" levels of vaccination to achieve herd immunity, as the vaccine would likely not work in everyone injected.

© 2020 AFP

Citation: WHO urges nations to join global shared vaccine bid (2020, August 18) retrieved 29 June 2024 from <https://medicalxpress.com/news/2020-08-urges-nations-global-vaccine.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.